Astrocytoma Clinical Trials

10 recruiting

Frequently Asked Questions

Common questions about Astrocytoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 45 trials

Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled41 locationsNCT06860594
Recruiting
Phase 1

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

GliomaRecurrent GlioblastomaAstrocytoma
National Cancer Institute (NCI)28 enrolled1 locationNCT06344130
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Childhood AstrocytomaChildhood Diffuse Intrinsic Pontine GliomaChildhood Diffuse Midline Glioma+2 more
Children's Oncology Group54 enrolled17 locationsNCT06894979
Recruiting
Early Phase 1

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

GlioblastomaGlioblastoma MultiformeHigh Grade Glioma+6 more
Nationwide Children's Hospital15 enrolled18 locationsNCT06333899
Recruiting
Not Applicable

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4

Glioblastoma (GBM)Astrocytoma, Grade IV
Sunnybrook Health Sciences Centre60 enrolled1 locationNCT07459101
Recruiting
Phase 3

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

GliomaAstrocytoma, IDH-Mutant, Grade 2Astrocytoma, Grade IV+5 more
Nuvation Bio Inc.365 enrolled45 locationsNCT05303519
Recruiting
Phase 1

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Recurrent GlioblastomaRecurrent Malignant GliomaRecurrent Gliosarcoma+2 more
M.D. Anderson Cancer Center36 enrolled1 locationNCT03896568
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled21 locationsNCT05843253
Recruiting
Phase 1Phase 2

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled6 locationsNCT06047379
Recruiting
Phase 1Phase 2

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III
Debiopharm International SA116 enrolled17 locationsNCT05765812
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388
Recruiting
Phase 2

Venous Thromboembolism Prevention in Outpatients With Glioma

GlioblastomaVenous ThromboembolismAstrocytoma
University of Vermont Medical Center40 enrolled1 locationNCT05683808
Recruiting
Phase 1Phase 2

Study of Pembrolizumab and M032 (NSC 733972)

Glioblastoma MultiformeAnaplastic AstrocytomaGliosarcoma
University of Alabama at Birmingham28 enrolled1 locationNCT05084430
Recruiting
Phase 1Phase 2

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom182 enrolled3 locationsNCT06630260
Recruiting
Phase 2

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

GlioblastomaOligodendrogliomaWHO Grade III Glioma+6 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04623931
Recruiting
Phase 1

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Central Nervous System NeoplasmsGlioblastomaOligodendroglioma+20 more
Jazz Pharmaceuticals102 enrolled1 locationNCT04541082
Recruiting
Phase 1

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

Brain TumorBrain CancerGlioblastoma+6 more
Henry Ford Health System18 enrolled1 locationNCT05686798
Recruiting
Phase 1Phase 2

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Glioblastoma MultiformeOligodendrogliomaDiffuse Intrinsic Pontine Glioma+5 more
University of Miami20 enrolled1 locationNCT05956821
Recruiting
Phase 1

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Resectable GlioblastomaIDH Wildtype GlioblastomaRecurrent Astrocytoma+2 more
Jonsson Comprehensive Cancer Center10 enrolled1 locationNCT07089641